Indolent Systemic Mastocytosis: The Role of Dermatologists for Early Diagnosis and Intervention

Discuss the heterogeneous and cutaneous clinical presentation of indolent systemic mastocytosis (ISM) as it relates to early diagnosis 

Identify patients with ISM based on the 2023 National Comprehensive Cancer Network (NCCN) guidelines  

Describe new and emerging targeted therapies available for the treatment of ISM

FC25: Indolent Systemic Mastocytosis: The Role of Dermatologists for Early Diagnosis and Intervention: An Online Activity

DermInsider - VGR Session 17

Describe the current evidence, indications, and clinical benefits of neoadjuvant therapy for advanced melanoma

Summarize current evidence-based strategies for the treatment and prevention of keratinocyte carcinoma

Update knowledge regarding recent advances in the safe and effective use of biologic agents for the treatment of dermatologic diseases

Identify and describe the indications, contraindications, and evidence-based safety and efficacy profiles of new agents approved for use in the dermatology setting

Melanoma and Non-Melanoma Skin Cancers: State-of-the Art Pearls and Data & Valuable Off-Label Treatments


DermInsider - A Virtual Grand Rounds Series - Session 17: Melanoma and Non-Melanoma Skin Cancers: State-of-the Art Pearls and Data & Valuable Off-Label Treatments

DermInsider - VGR Session 16

Describe the use of adjuvant therapies for challenging cases of squamous cell carcinoma

Explain the use of imaging modalities for high risk cases of keratinocyte carcinoma

Critique and compare emerging and established treatment options for hyperhidrosis

Summarize current evidence-based approaches to diagnosing and classifying hyperhidrosis

Tough Cases From a Mohs Surgeon and Evolving Therapies in Hyperhidrosis


DermInsider - A Virtual Grand Rounds Series - Session 16: Tough Cases From a Mohs Surgeon & Evolving Therapies in Hyperhidrosis

DermInsider - VGR Session 15

Describe recent advances and emerging therapies in the management of inflammatory and pruritic dermatologic disorders, including atopic dermatitis, psoriatic disease, and hidradenitis suppurativa

Implement evidence-based strategies to optimize diagnosis and individualized treatment approaches for complex skin and hair disorders such as pyoderma gangrenosum and alopecia areata

From A(D) to Z: Rapid Therapeutic Updates Across the Dermatology Spectrum

DermInsider - A Virtual Grand Rounds Series - Session 15: From A(D) to Z: Rapid Therapeutic Updates Across the Dermatology Spectrum

DermInsider - VGR Session 13

Develop and implement evidence-informed, non-pharmacologic and adjunctive strategies to enhance symptom control, treatment adherence, and quality of life in patients with atopic dermatitis and psoriasis

Implement practical approaches to navigate therapeutic barriers—such as insurance denials, treatment availability, and patient-specific limitations—using clinical justification, coding strategies, and patient education.

Summarize effective methods to empower patients, through targeted education and low-risk lifestyle modifications, to support self-management of chronic inflammatory skin diseases

30 Expert Tips in 30 Minutes: Patient-Centered Pearls

DermInsider - A Virtual Grand Rounds Series - Session 13: 30 Expert Tips in 30 Minutes: Patient-Centered Pearls 

DermInsider - VGR Session 12

Define the role of targeted biologics in the management of various dermatologic conditions based on the latest real-world and long-term clinical evidence

Apply recent clinical data for biologic therapies into the management of moderate-to-severe AD in order to prevent progression


Assess the expanding role of cosmeceuticals in dermatologic practice, considering recent advances in formulation, mechanism of action, and clinical application

The Changing Landscape of Topical Therapies - Recorded Live at Fall Clinical 2025

DermInsider - A Virtual Grand Rounds Series - Session 12: The Changing Landscape of Topical Therapies

DermInsider - VGR Session 11

Describe new developments in treatment of acne and acne sequelae

Describe new developments in rosacea therapy

Apply knowledge of Botulinum Toxin Type A’s mechanism, onset, duration, and diffusion characteristics to optimize treatment outcomes and minimize adverse effects in clinical practice

Identify safe practices for aesthetic procedures and describe potential complications

The Science of Botulinum Toxin Type A and Clinical Updates in Acne & Rosacea 

DermInsider - A Virtual Grand Rounds Series - Session 11: The Science of Botulinum Toxin Type A & Clinical Updates in Acne and Rosacea

Patient Questions on GLP-1’s – Let’s Talk About It! Instagram Live

Identify strategies for integrating GLP-1 receptor agonists into dermatology practice, considering patient support programs to improve access and adherence.  

Patient Questions on GLP-1’s – Let’s Talk About It! Instagram Live: An Online Activity

DermInsider - VGR Session 10

Outline diagnostic and therapeutic strategies for several unusual rashes.

Identify and discuss several cutaneous eruptions to avoid making assumptions about the likelihood of a diagnosis based on a patient's demographic features.

"I’ve Got This Weird Rash…” What’s the Diagnosis? Special Case Challenge Competition

DermInsider - A Virtual Grand Rounds Series - Session 10: "I’ve Got This Weird Rash…” Special Case Challenge Competition

Patient Questions on GLP-1’s – Let’s Talk About It!

DermInsider - VGR Session 8

Summarize the pathophysiology of cutaneous disease to improve the selection of targeted treatments for individual patients

Describe morphological characteristics of specific dermatologic diseases to help generate a broad differential diagnosis

What’s the Diagnosis? Special Case Challenge Competition

DermInsider - A Virtual Grand Rounds Series - Session 8: What’s the Diagnosis? Special Case Challenge Competition

DermInsider - VGR Session 7

Discuss the pathogenesis and optimal management of psoriasis, atopic dermatitis and acne vulgaris


Update knowledge regarding recent advances in the safe and effective use of biologic agents for the treatment of dermatologic diseases


Enhance the ability to evaluate and incorporate new techniques and uses of dermal fillers and neurotoxins


Identify and describe the indications, contraindications, and evidence-based safety and efficacy profiles of new agents approved for use in the dermatology setting Integrate prevention, diagnosis, and management of skin cancer into my clinical setting


Diagnose commonly presented dermatologic disorders


Improve clinical interactions with patients


Integrate knowledge to enhance daily dermatologic care


A Review of the most recent updates on: Acne, Aesthetic Dermatology, Atopic Dermatitis, Psoriasis, Rosacea, Skin Cancer and More!

DermInsider - A Virtual Grand Rounds Series - Session 7: Mid Year Recap: News, Insights, & Takeaways from the First Half of 2025

DermInsider - VGR Session 5

Review tips and tricks for biologic and small molecules in inflammatory patients

Incorporate best practices for improving efficiency in a busy Dermatology Clinic

Describe the mechanism of action and spectrum of therapeutic benefits of azelaic acid

Evaluate the uses and benefits of tranexamic acid to decrease blood loss in dermatologic procedures

40 Tips in 40 Minutes

DermInsider - A Virtual Grand Rounds Series - Session 5: 40 Tips in 40 Minutes

Case-Based Insights for Systemic Therapies in Basal Cell Carcinoma

Assess the role of systemic therapies for the management of basal cell carcinoma (BCC) 

Select appropriate therapies for patients with BCC based on the 2024 National Comprehensive Cancer Network guideline recommendations

WCM25: Case-Based Insights for Systemic Therapies in Basal Cell Carcinoma: An Online Activity

DermInsider - VGR Session 1

Discuss the pathogenesis and optimal management of psoriasis, atopic dermatitis and acne vulgaris

Enhance the ability to evaluate and incorporate new techniques and uses of dermal fillers and neurotoxins

Identify and describe the indications, contraindications, and evidence-based safety and efficacy profiles of new agents
approved for use in the dermatology setting

Integrate prevention, diagnosis, and management of skin cancer into my clinical setting

Diagnose commonly presented dermatologic disorders

Improve my clinical interactions with patients

Integrate knowledge to enhance daily dermatologic care

Breaking News Edition: News, Insights, & Takeaways from the Early 2025 Dermatology Conferences

DermInsider - A Virtual Grand Rounds Series Session 1: March 12, 2025

Identify and describe the indications, contraindications, and evidence-based safety and efficacy profiles of new agents
approved for use in the dermatology setting Integrate prevention, diagnosis, and management of skin cancer into my clinical setting

2024 Virtual Grand Rounds Session 15: November 13, 2024 - What Did 2024 Bring to the Table in Dermatology? Best of FC24 Clinical Review

2024 Virtual Grand Rounds Session 14: November 6, 2024 - Highlights from Fall Clinical 2024: Your Questions Answered

Describe how to assess patients with diverse cultural backgrounds, SOC, and sexual orientation

Review treatment options for common dermatoses seen in diverse patient populations

Employ strategies to effectively communicate with patients with diverse cultural backgrounds, SOC, and sexual orientation 

'5 in 5' Five Tips to Improve Clinical Care for Diverse Patient Populations: An Online Activity

Enhance your ability to diagnose, manage, and treat with the most current treatment options

Identify patients who may benefit from new approaches to difficult to manage diseases

Apply best practices for enhancing patient communication and shared decision-making techniques

Decipher clinical trial data and guidelines and how to apply them to every day practice

2024 Virtual Grand Rounds Session 7: May 8, 2024 - 60 Tips in 60 Minutes

Recognize the clinical presentation of GPP and how to diagnose it

Be familiar with the current GPP treatment options such as the IL-36 pathway 

Discuss the implications of alternatives to oral antibiotics and hormonal therapies for moderate acne vulgaris 

Assess whether patients with moderate Acne Vulgaris can benefit from weekly isotretinoin therapy 

2024 Virtual Grand Rounds Session 5: April 3, 2024 -E-Journal Club Edition: What's New in SKIN, The Journal of Cutaneous Medicine

Discuss the treatment of psoriasis and related disorders with evolving therapies

Recognize the various therapies available for acne and their role in clinical practice

Translate the role of therapies for eczema in clinical practice

Describe the modalities for diagnosing and managing skin cancer

Identify optimal patients for the use of fillers and botulinum

Describe strategies to prepare and administer fillers and botulinum

Illustrate strategies to manage dermatologic conditions effectively in clinical practice

2024 Virtual Grand Rounds Session 1: January 31, 2024 - WCH24 Your Questions Answered

Identify common dermatoses presentations in patients with skin of color (SOC)

Employ strategies to effectively communicate with patients with diverse cultural backgrounds, SOC, and sexual orientation

Difficult Dermatology Conversations: Improving Care for Diverse Patient Populations 

Identify optimal patients for the use of fillers and botulinum 

2023 Virtual Grand Rounds Session 14: November 15, 2023 - Fall Clinical 2023- Your Questions Answered

Recognize that IL-4 and IL-13 are signature cytokines of type 2 inflammatory response

Understand that Type 2 inflammatory response involves mast cells, eosinophils, and basophils 

Recognize the common signs and symptoms of Staph Scalded Skin Syndrome

Understand treatment of Staph Scalded Skin Syndrome

Recognize the rare benign vascular disorder of Achenbach Syndrome

Understand the differential diagnosis and workup of Achenbach Syndrome

2023 Virtual Grand Rounds Session 13: September 27, 2023 - Challenging Cases in Dermatology

Dermatology

WEDNESDAY, Dec. 3, 2025 (HealthDay News) -- Both a lower-cost, ambient-light, nonpolarized dermatoscope and a higher-cost, illuminated, polarized dermatoscope enable patients to perform dermoscopy and receive teledermatology recommendations, according to a study published online Dec. 3 in JAMA Dermatology.Deonna M. Ackermann, M.P.H., from the University of Sydney, and colleagues compared a lower-cost ambient-light, nonpolarized dermatoscope to a higher-cost, illuminated, polarized dermatoscope for patient-performed teledermoscopy following early-stage melanoma treatment. The study included adults previously treated for early-stage melanoma in the patient-led surveillance arm of the MEL-SELF trial.Of 251 participants, 175 received a teledermatologist management recommendation for baseline images (polarized: 71.9 percent; ambient light: 67.5 percent). The researchers found that the proportion who received at least one recommendation was similar between the groups by 12 months (81.3 percent for polarized; 76.4 percent for ambient light). A per-image analysis showed more polarized images than ambient-light images were reportable and supported a recommendation (95.0 versus 91.1 percent). More positive feedback was provided for polarized images by teledermatologists, with blurriness (14 versus nine) and poor lighting (six versus zero) occurring more often with ambient light images. Patient usability ratings were similar (moderately/very easy, 39.8 versus 36.6 percent); more image quality issues were reported by ambient light dermatoscope users. The cost of the polarized device was higher ($324.16 versus $35.40)."Decisions to adopt a particular device should consider not only image quality but also costs, user training requirements, and implementation feasibility," the authors write.Several authors disclosed ties to the medical device, biotechnology, and dermatology industries.<a target="_blank" rel="noopener noreferrer" href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2841807">Abstract/Full Text</a>

Ambient light and polarized dermatoscopes both enable dermoscopy performance and receipt of teledermatology recommendations

Dermatoscopes Compared for Dermoscopy Performance, Teledermatology Use

When Amy Jones, PA-C, first stepped into emergency medicine, she didn’t yet know her calling would lead her to dermatology, and ultimately to building something new for her peers.After 15 years in dermatology and medical affairs, Jones has become one of the driving forces behind PANP360, a new learning hub and community designed by and for advanced practice providers in dermatology. Her vision: to create a space where PAs and NPs can find comprehensive education, clinical confidence, and a sense of connection that extends beyond CME.“If we don’t take care of ourselves, we can’t take care of patients,” Jones says. “Helping people master their craft so they feel confident in the care they provide—and also learn how to be well-rounded humans—is how we prolong our ability to see patients and live our lives to the fullest.”<h4>Amy’s Story from the ER to Dermatology</h4>What originally drew you to dermatology? I had practiced in emergency medicine, and that was very procedural-based and fast-paced. I knew after doing that for a few years that it was a young person’s game; it’s hard on the body and the lack of sleep is rough. I wanted that broad foundation of treating patients, but I knew it wasn’t a long-term fit for me.One of my PA school friends said, “You should look at derm. Everyone who does derm is really happy.” I started shadowing a PA near my home, and he was great. He let me learn the ropes from him. When their practice had an opportunity to add a PA, they offered it to me. That was a huge blessing.What changed for you once you transitioned into dermatology?&nbsp; I knew dermatology was going to be good, but I didn’t realize what was missing in the ER—the patient connection. In emergency medicine, you never have continuity; you see a different patient every time.Once I started having that in dermatology, it changed my life. I felt like I was part of something. I was able to recognize my patients, ask about their lives without reviewing their chart, "Your child graduated? Where did they go to college?” Those types of things really made me feel connected. That’s what dermatology did that I really loved.<h4>The Future of Care: PA and NP Leadership</h4>How have you seen the role of PAs and NPs evolve in dermatology?&nbsp; Dermatology is underserved, and I’ve really seen PAs and NPs fill that gap, especially in more rural areas. They’re setting up clinics, sometimes practicing independently or with collaborating physicians available by phone. That’s something that’s definitely changed over time.PAs and NPs are the future of medicine—definitely the future of dermatology. They’re a workforce trained to take care of patients at an advanced practice level, and that need is only going to keep growing.<h4>Building PANP360 Starts with a Holistic Approach</h4>What makes PANP360 different?&nbsp; I really want to focus on holistic healthcare providers who can take holistic care of patients. Once you’re complete in your knowledge and in your self-care journey, that spills over into your ability to take care of patients. That’s where the ‘360’ comes from—the well-rounded view of not only practitioner care, but patient care.How will the hub reflect that vision?&nbsp; The hub will be a great place to get all kinds of information at your fingertips, all year long. It’s intended to create a customized journey for PAs and NPs—no matter where you’re at in your practice.Whether you’re a student, new to practice, or you’ve been around for 20+ years, you’ll get content that meets you where you are—videos, articles, podcasts, Q&amp;As with experts, social media live streams. You’ll be immersed in the topics that matter most.<h4>Collaboration and Community</h4>You’ve said it’s important that this be by and for PAs and NPs. How will that show up?&nbsp; I would love for anybody who’s part of our community to be part of creating the content. PAs and NPs know what we need to take care of patients and where are the gaps or what topics have new developments. I really want to encourage people to be part of shaping the future and come along on the journey with us.I’d love to see PAs and NPs writing editorials, lecturing from the podium, joining panel discussions with physicians—getting involved at every turn in the future of dermatology. I want this to be a place where that happens, where people get recognized for what they contribute.<h4>Continuous Learning, Real-Time Relevance</h4>How will PANP360 help clinicians stay current and confident in real time?&nbsp; PANP360 will always be committed to cutting-edge education all year long. The learning experience is meant to cover hot topics—what’s most relevant to you and your practice at any given time.We’ll have timeless content you can learn from anytime, but also updates on what’s new, what’s trending, and what’s changing in the field.What do you hope every PA and NP takes away from this community?&nbsp; I want PAs and NPs to feel valued. Day-to-day clinic life can be monotonous sometimes. It can be thankless. I want them to know that what they do matters, that patients value them, and that we value them. We see you, and we want to make your practice and your life better.And if you could send a message to your peers across dermatology?&nbsp; This matters because patients need us. Patients need healthcare providers educated to the highest level and ability, providing the standard of care regardless of credentials. Patients deserve the best, and PAs and NPs are the future of making that happen.<h4>A Community You Won’t Want to Miss</h4>What excites you most about what’s coming next?&nbsp; I think we’ll be able to create a community people can’t wait to be part of. They’ll see the fruits of what they’re contributing to, feel ownership over how programming evolves, and feel so ingrained in what we’re building that they don’t want to miss a thing.PANP360 launches this January as Dermsquared’s newest hub for dermatology PAs and NPs—a place for education, connection, and collective growth.&nbsp;

PANP360 brings dermatology PAs and NPs a place to learn, connect, and grow—clinically and as whole people.

Introducing Amy Jones and PANP360: A New Era for PAs and NPs in Dermatology

WEDNESDAY, Nov. 19, 2025 (HealthDay News) -- For patients with keloids, intralesional triamcinolone acetonide (TAC), intralesional bleomycin, and intralesional radiofrequency ablation (RFA) are all effective, with the greatest efficacy seen for TAC, according to a study published online in the November issue of SKIN.Aarti Singh, from Indira Gandhi Medical College in Shimla, India, and colleagues compared the efficacy and side effect profiles of intralesional TAC, intralesional bleomycin, and intralesional RFA for management of keloids in a randomized trial. A total of 117 patients were enrolled and randomly assigned to receive TAC, bleomycin, or RFA (groups A, B, and C, respectively); nine patients were lost to follow-up. The Patient and Observer Scar Assessment Scale (POSAS) was used to assess treatment efficacy.The researchers found that compared with baseline, all three groups had significant reductions in POSAS scores. Therapeutic effectiveness was 100, 80.6, and 72.2 percent in groups A, B, and C, respectively. Seventy-two percent of patients in groups A and B and 83.3 percent in Group C had side effects. During the eight-week follow-up after treatment completion, no recurrence was observed."TAC emerged as the most effective therapy, followed by bleomycin and RFA. While RFA showed lower efficacy and higher side effects, it holds promise as a noninvasive alternative, particularly with protocol optimization," the authors write. "Future studies exploring combination therapies and longer-term outcomes will help refine individualized keloid treatment strategies."<a target="_blank" rel="noopener noreferrer" href="https://skin.dermsquared.com/skin/article/view/3621">Abstract/Full Text</a>

Intralesional triamcinolone acetonide had greatest efficacy, with relatively favorable side effect profile

Study Compares Treatment Modalities for Management of Keloids

WEDNESDAY, Nov. 5, 2025 (HealthDay News) -- Patients with dermatomyositis who use immunostimulatory herbs before disease onset have lower positivity rates of myositis-associated autoantibodies (MAAs), myositis-specific autoantibodies (MSAs), and antinuclear autoantibodies (ANAs), according to a research letter published online Nov. 5 in JAMA Dermatology.In a retrospective cohort study, Xiwei Yang, from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues examined whether commercial autoantibody testing results differ for patients with dermatomyositis that developed with versus without prior intake of immunostimulatory herbs. Positivity rates of MAAs, MSAs, and ANAs were compared for patients with versus without preonset herbal exposure; any herbal intake that lasted until three months before onset was considered relevant.The researchers found that 36 (13 percent) of 286 patients used immunostimulatory herbs prior to developing dermatomyositis symptoms. The median time was 12 months from first herbal use to dermatomyositis onset. The most commonly taken herb was spirulina (22 of 36 [61 percent]). Compared with the nonherbal intake group, the MSA positivity rate was lower in the herbal intake group (22 versus 51 percent), as was the MAA positivity rate (13 versus 32 percent). The herbal intake group also had a lower rate of ANA positivity (40 versus 61 percent)."Individuals susceptible to developing autoimmune responses should be counseled about the possible risk of herbal use until the pathway is further elucidated," the authors write.Several authors disclosed ties to the biopharmaceutical industry.<a target="_blank" rel="noopener noreferrer" href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2841139">Abstract/Full Text</a>

Patients with dermatomyositis who used immunostimulatory herbs before onset have lower rates of MAA, MSA, ANA positivity

Lower Autoantibody Positivity Seen With Herbal Intake Before Dermatomyositis

TUESDAY, Nov. 4, 2025 (HealthDay News) -- Two human leukocyte antigen (HLA) class I alleles are independently associated with an increased risk for allopurinol-induced severe cutaneous adverse reactions (SCARs), according to a study published online Oct. 29 in JAMA Dermatology.Chelsea N. Campbell, from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues examined the association of HLA class I and II among U.S. patients who received a diagnosis of allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms compared to allopurinol-tolerant and population control participants. Participants were identified from the Vanderbilt University Medical Center biobank, which includes 94,489 individuals with imputed HLA class I and II typing.The genetic association study included 16 patients with allopurinol-induced SCAR and 160 allopurinol-tolerant control participants. The researchers found independent associations for two HLA class I alleles with an increased risk for allopurinol-induced SCAR: HLA-B*58:01 and HLA-A*34:02 (odds ratios, 28.0 and 20.6, respectively). There were no HLA class II alleles that met the Bonferroni-corrected P &lt; 0.05 level of significance."We found a new genetic association, HLA-A*34:02, which appears very important as a risk factor in U.S. allopurinol severe cutaneous adverse reactions patients," coauthor Elizabeth J. Phillips, M.D., also from Vanderbilt University Medical Center, said in a statement. "The combination of HLA-A*34:02 and HLA-B*58:01 would help explain risk in over 80 percent of patients."One author disclosed ties to the pharmaceutical and medical technology industries.<a target="_blank" rel="noopener noreferrer" href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2840445">Abstract/Full Text</a>

HLA-B*58:01 and HLA-A*34:02 linked to increased risk, while no HLA class II alleles were identified

Two HLA Class I Alleles Independently Linked to Allopurinol-Induced SCARs

WEDNESDAY, Oct. 22, 2025 (HealthDay News) -- Hydrocolloid dressing (HCD) is a suitable postoperative option after dermatologic surgery, with similar scar appearance and complication rates relative to daily petroleum ointment, according to a study published online Oct. 22 in JAMA Dermatology.Maria C. Bell, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues compared scar appearance and surgical complications with a one-time application of HCD for one week after excisional surgery versus daily petroleum ointment in a randomized clinical trial. A total of 146 adult patients undergoing standard excision or Mohs micrographic surgery with linear bilayered repair were randomly assigned: 72 and 74 to HCD and petroleum ointment, respectively.The researchers found that for overall appearance, surgeon and patient ratings were clinically comparable. The difference in mean Visual Analog Scale rating between HCD and petroleum groups was –0.40, –0.08, and –0.09 at seven, 30, and 90 days, respectively. Higher, but not statistically significant, rates of adverse events were seen for the HCD group, including postoperative bleeding, wound dehiscence, and surgical site pain. Postoperative antibiotics were not required by any patients. A higher proportion of patients in the HCD group versus the petroleum ointment group rated the HCD as convenient or extremely convenient (86.9 versus 46.8 percent) and comfortable or extremely comfortable (73.8 versus 48.3 percent)."The clinical decision to use HCD versus daily petroleum ointment should balance cost and patient preferences for convenience and comfort with their risk of postoperative complications," the authors write. "The ability to wear HCD continuously for the first week after surgery provides a practical benefit, especially for patients who find daily dressing changes challenging or tedious."<a target="_blank" rel="noopener noreferrer" href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2840407">Abstract/Full Text</a>

Scar appearance and complication rates similar to those seen with daily petroleum ointment

Hydrocolloid Dressing Suitable Option After Dermatologic Surgery

FRIDAY, Oct. 17, 2025 (HealthDay News) -- For people with HIV (PWH), the incidence of dermatologic disease (DD) has decreased over time but still remains prevalent, according to a study published online Oct. 14 in the Journal of the American Academy of Dermatology.Yagiz Matthew Akiska, from The George Washington University in the District of Columbia, and colleagues characterized the prevalence, incidence, and risk factors of DD among PWH in a longitudinal cohort study involving 11,738 adults enrolled in a cohort between 2011 and 2023. DDs were categorized as infectious dermatoses, inflammatory dermatoses, or cutaneous malignancies (CM).The researchers found that 49.4 percent of the participants had one or more dermatologic diagnosis, with infectious conditions the most common (41.4 percent). From 2011 to 2024, there was a decline in incidence across all categories of DD, including infectious (463 to 41), inflammatory (306 to 62), and CM (31 to six) cases per 1,000. The odds of CM were more than sixfold greater among cisgender females. Higher DD risk was seen in association with lower nadir CD4 count, older age, public insurance, and prior opportunistic infections."As the population of people living with HIV ages, chronic skin conditions are becoming more prominent and often persist despite effective HIV treatment," Akiska said in a statement. "Addressing these issues requires integrating dermatology into HIV care, so that patients receive comprehensive support for both their overall health and their quality of life."<a target="_blank" rel="noopener noreferrer" href="https://www.sciencedirect.com/science/article/abs/pii/S019096222502804X?dgcid=author">Abstract/Full Text</a>

Associations with higher dermatologic disease risk seen for lower nadir CD4 count, older age, public insurance

Incidence of Dermatologic Disease Persists in People With HIV

Plano, Texas - October 27, 2025-- <a href="/" target="_blank" rel="noopener noreferrer">Dermsquared</a> is proud to announce the launch of <a href="/panp" target="_blank" rel="noopener noreferrer">PANP360</a>, a reimagined hub built entirely for dermatology physician assistants and nurse practitioners. More than a website, PANP360 marks the start of a movement—one where advanced practice clinicians can connect, learn, and lead the future of dermatologic care together. &nbsp;As a living community, the new platform offers exclusive educational experiences, clinical conversations, podcasts, ways to directly connect, and practical tools designed by and for PAs and NPs, all within an ecosystem that recognizes their expertise as essential to the specialty’s growth. &nbsp;“There’s a lot of talk about ‘KOLs,’ and I think we’re all key opinion leaders in our own spaces—in our clinics, in our mentorship, in our daily decisions,” says <a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/in/amy-baum-jones-a40260159/">Amy Jones, PA-C</a>, dermatology clinician and PANP360 editorial advisor. “Everyone has something to teach, whether you’ve been practicing for two years or twenty. PANP360 gives those voices a place to be heard.”With this launch, PANP360 underscores the idea that professional growth and personal well-being are inseparable. Its evolving lineup of on-demand education, live discussions, and peer-led stories highlights real-world experience as a cornerstone of clinical excellence long after the conference is over.“If we don’t take care of ourselves, we can’t take care of patients,” Jones adds. “Helping people master their craft so they feel confident in the care they provide, and also learn how to be well-rounded humans, is how we prolong our ability to see patients and live our lives to the fullest.”“PANP360 is an embodiment of what we believe at Dermsquared—that education isn’t just courses or credits; it’s about connection,” says Eric Bruno, CEO of HCEsquared, the parent company of Dermsquared. “By creating a community where every clinician’s insight matters, we’re redefining how learning happens through shared experience.”And while Dermsquared continues to serve as the trusted destination for every dermatology clinician, PANP360 extends that mission, offering an advanced practice hub where PAs and NPs can find content tailored to their unique roles and challenges. &nbsp;Together, they represent the only dermatology ecosystem designed to support the full 360 of the practice, 365 days a year. A space built by peers, powered by purpose, and grounded in connection._____________About PANP360<a href="/panp" target="_blank" rel="noopener noreferrer">PANP360</a> is the peer-driven hub for dermatology physician assistants and nurse practitioners, built by Dermsquared, the leading digital platform for dermatology education. PANP360 delivers immersive learning experiences, community connection, and practical tools that support professional growth and clinical excellence across all settings of dermatologic care.About DermsquaredFounded by dermatology professionals who envisioned better ways to learn and connect, Dermsquared is the only community-based platform designed to support the entire dermatology practice team. Through meaningful, peer-driven collaboration with respected leaders in the field, Dermsquared delivers expert-led education, on-demand learning, certification programs, live events, and practical clinical resources. Trusted by top key opinion leaders and valued by industry partners, Dermsquared empowers professionals across the care continuum to elevate patient outcomes, advance their careers, and strengthen the specialty as a whole.

The one-of-a-kind platform unites peer connection, clinical learning, and purpose under one home

A New Era for Dermatology PAs and NPs Begins with PANP360

Plano, Texas - October 21, 2025 - <a href="/" target="_blank" rel="noopener noreferrer">Dermsquared</a>, the leading community-based platform for dermatology professionals, today announced the appointment of April Armstrong, MD, MPH, as Editor-in-Chief of the <a target="_blank" rel="noopener noreferrer" href="https://doj.dermsquared.com/index.php/doj">Dermatology Online Journal</a> (DOJ). Dr. Armstrong succeeds Barbara Burrall, MD, continuing the journal’s nearly three-decade legacy of advancing open-access dermatologic scholarship.Dr. Armstrong is an internationally recognized dermatologist, researcher, and educator, whose work has helped define evidence-based approaches in dermatology practice and research. As Editor-in-Chief, she will guide the journal’s strategic direction while upholding its longstanding commitment to editorial excellence and scientific rigor.“I am deeply honored to join the legacy of the Dermatology Online Journal and to build upon the exceptional work of Dr. Barbara Burrall and the editorial team,” said Dr. Armstrong. “Together with Dr. Nicholas Brownstone and the Dermsquared team, I look forward to advancing evidence-based dermatology and bringing innovative research and practical clinical insights to clinicians and researchers alike.”“Dr. Armstrong’s appointment marks an exciting new chapter for the Dermatology Online Journal,” said Eric Bruno, CEO of HCEsquared, the parent company of Dermsquared. “Her leadership, research acumen, and editorial experience make her uniquely qualified to guide the journal’s continued growth and relevance in a rapidly evolving field.”Founded in 1995, the Dermatology Online Journal is among the longest-running open-access publications in dermatology. Under Dr. Armstrong’s leadership, DOJ will continue to publish timely, evidence-based content that supports clinical decision-making and advances the specialty worldwide.About April Armstrong, MD, MPHAn internationally recognized leader in inflammatory skin diseases, including psoriasis and atopic dermatitis, Dr. Armstrong is widely regarded for her expertise in clinical trials and health outcomes research in dermatology. Her extensive work has shaped modern dermatologic practice and therapeutic innovation, bridging clinical research, digital health, and real-world evidence to improve patient outcomes and access to care.Dr. Armstrong has served on the editorial boards of major scientific journals and is a staunch advocate for dermatology, having held leadership roles in the American Academy of Dermatology, National Psoriasis Foundation, GRAPPA, International Eczema Council, and IDEOM. Before joining UCLA, Dr. Armstrong was Associate Dean for Clinical Research at the University of Southern California. She earned her MD, MPH, and completed dermatology residency at Harvard. As Editor-in-Chief, Dr. Armstrong aims to propel Dermatology Online Journal into its next era of excellence by advancing high-quality, evidence-based content that informs clinical practice, inspires innovation, and encourages global collaboration within the dermatology community.About Dermatology Online JournalFounded in 1995 by Arthur C. Huntley, MD, <a target="_blank" rel="noopener noreferrer" href="https://doj.dermsquared.com/index.php/doj">Dermatology Online Journal</a> (DOJ) is recognized as the first open-access, peer-reviewed medical journal on the internet. Since its inception, DOJ has been dedicated to advancing dermatologic science and improving how scholarly content is shared and accessed worldwide.What began as a pioneering experiment in digital publishing has evolved into a leading bi-monthly journal publishing more than 20 peer-reviewed articles per month. Indexed on PubMed for over a decade, DOJ continues to provide a trusted forum for clinicians, researchers, and educators to exchange evidence-based insights and emerging discoveries in dermatology.Today, DOJ engages a diverse international community of contributors and reviewers—over 700 physicians and academic experts spanning multiple continents—who help maintain its longstanding commitment to scientific rigor, accessibility, and innovation in medical publishing.About DermsquaredFounded by dermatology professionals who envisioned better ways to learn and connect, Dermsquared is the only community-based platform designed to support the entire dermatology practice team. Through meaningful, peer-driven collaboration with respected leaders in the field, Dermsquared delivers expert-led education, on-demand learning, certification programs, live events, and practical clinical resources. Trusted by top key opinion leaders and valued by industry partners, Dermsquared empowers professionals across the care continuum to elevate patient outcomes, advance their careers, and strengthen the specialty as a whole.

April Armstrong, MD, MPH, announced as Editor-in-Chief of Dermatology Online Journal

Dermsquared Appoints April Armstrong, MD, MPH, as Editor-in-Chief of the Dermatology Online Journal

Key Takeaways<ul><li>32 DermaRite products are being recalled for possible bacteria contamination</li><li>The bacteria can cause severe infections</li><li>Affected items include soaps, sanitizers, lotions and wound cleansers</li></ul>WEDNESDAY, Sept. 17, 2025 (HealthDay News) — DermaRite Industries has widened its earlier recall of hand soaps to include 32 personal care products that could be contaminated with a dangerous bacteria, health officials report.The New Jersey-based <a target="_blank" rel="noopener noreferrer" href="https://dermarite.com/">company</a> said the recalled items include body washes, lotions, soaps, shampoos, sanitizers and wound cleansers sold nationwide and in Puerto Rico.The products are often used in hospitals and nursing homes, but some are also sold by other retailers.The bacteria in question, Burkholderia cepacia complex, can cause serious and sometimes life-threatening infections in people with weakened immune systems or those caring for them, according to the company.Even generally healthy people could develop infections if they have cuts or skin lesions.The voluntary recall does not affect DermaRite’s nutritional products, the company said.Customers should stop using the recalled products immediately and return them.More informationDermaRite has the <a target="_blank" rel="noopener noreferrer" href="https://dermarite.com/dermarite-expands-voluntary-nationwide-recall/">full list of recalled products.</a>SOURCE: OregonLive, Sept. 11, 2025

Recalled items include body washes, lotions, soaps, shampoos, sanitizers and wound cleansers sold nationwide and in Puerto Rico

DermaRite Widens Recall to 32 Products Over Bacteria Risk

Key Takeaways<ul><li>DermaRite has expanded its recall to include more products</li><li>The products may be contaminated with bacteria that can cause serious infections</li><li>People with weakened immune systems face the highest risk</li></ul>WEDNESDAY, Sept. 3, 2025 (HealthDay News) — <a target="_blank" rel="noopener noreferrer" href="https://dermarite.com/">DermaRite</a> Industries has expanded a voluntary recall of several over-the-counter creams, soaps and sanitizers that may be contaminated with <a target="_blank" rel="noopener noreferrer" href="https://www.cdc.gov/b-cepacia/about/index.html">Burkholderia cepacia complex</a>, a type of bacteria that can cause serious infections.The recall, first announced July 16, now includes additional products and lot numbers sold nationwide and in Puerto Rico, according to the U.S. Food and Drug Administration (FDA).Health officials warn that people with weakened immune systems face the greatest risk.In rare cases, the bacteria can cause severe infections that may lead to life-threatening <a target="_blank" rel="noopener noreferrer" href="https://www.healthday.com/a-to-z-health/blood-disorders/sepsis-2666029199.html">sepsis</a>. For healthy people, using the products may only cause minor skin infections, but health officials urge caution.The expanded recall covers a range of products, including:<ul><li>4-N-1 no-rinse wash cream</li><li>DermaCerin moisturizing cream</li><li>DermaFungal anti-fungal cream</li><li>DermaKleen antiseptic lotion soap</li><li>DermaMed skin protectant for poison ivy and other rashes</li><li>DermaSarra anti-itch cream</li><li>Gel Rite instant hand sanitizer</li><li>Hand E Foam foaming hand sanitizer</li><li>KleenFoam antimicrobial foam soap</li><li>Lantiseptic skin protectant for cuts and scrapes</li><li>PeriGiene antiseptic cleanser</li><li>PeriGuard skin protectant for incontinence-related rashes</li><li>Renew creams for diaper rash and skin repair</li><li>UltraSure antiperspirant and deodorant</li></ul>DermaRite has contacted distributors and customers and instructed them to destroy all affected products, the FDA said.Consumers with questions can call DermaRite directly at 888-943-5190 (Monday through Friday, 8 a.m. to 5 p.m. ET) or email dermarite5186@sedgwick.com.Anyone who develops symptoms after using these products should contact their health care provider right away.More informationA full list of affected products and lots is available on <a target="_blank" rel="noopener noreferrer" href="https://dermarite.com/voluntary-recall/">DermaRite.com</a>.SOURCE: U.S. Food and Drug Administration, recall notice, Aug. 28, 2025What This Means For YouConsumers should check their cabinets and health care supplies for affected DermaRite products and stop using them immediately if they're on the recall list.

Products may be contaminated with bacteria that can cause serious infections

DermaRite Expands Recall of Creams and Sanitizers Over Infection Risk

TUESDAY, Aug. 12, 2025 (HealthDay News) -- Most individuals living in underserved communities believe that dermatologic side effects (DSEs) from anticancer therapies (ACTs) occur at high rates, according to a study published online in the August issue of the Journal of Drugs in Dermatology.Nikita Menta, from George Washington University in Washington, D.C., and colleagues evaluated knowledge and perceptions of ACT (medication or radiation)-related DSEs in a medically underserved community. The analysis included survey responses from 77 individuals attending two health fairs.The researchers found that 21 percent of respondents were previously treated for cancer. Overall, most respondents believed that ACTs cause hair loss (52 percent overall versus 31 percent of respondents previously treated for cancer), dry skin/rash (47 versus 50 percent), and nail changes (41 versus 31 percent). Respondents most frequently reported the DSEs that would make them possibly or definitely not undergo treatment were permanent hair loss (33 percent overall versus 13 percent of respondents previously treated for cancer), temporary eyebrow/eyelash hair loss (27 versus 13 percent), and permanent nail discoloration (24 versus 13 percent). Among patients who were previously treated for cancer, half did not visit a dermatologist during cancer treatment."These data underscore the need for improved DSE management," the authors write. "Dermatologists should educate oncologists and primary care physicians on patients’ experiences undergoing ACT and treatments for DSEs."Several authors disclosed ties to industry.<a target="_blank" rel="noopener noreferrer" href="https://jddonline.com/articles/perceptions-knowledge-of-dermatologic-side-effects-of-anti-cancer-therapies-pilot-survey-S1545961625P9110X">Abstract/Full Text</a>

Findings seen among both those previously treated for cancer and cancer-naive people

Public Believes Dermatologic Side Effects From Cancer Treatment Are Common

WEDNESDAY, July 9, 2025 (HealthDay News) -- The Ichthyosis Scoring System (ISS) can be used across phototypes to measure the severity of ichthyosis, according to a study published online July 9 in JAMA Dermatology.Angela J. Luo, from the Yale School of Medicine in New Haven, Connecticut, and colleagues examined the reliability of the ISS in individuals with Fitzpatrick IV to VI skin types in a cross-sectional study. Fourteen dermatologists used the ISS to rate 94 test photographs, 47 each from individuals with Fitzpatrick I to III and IV to VI skin types. Four body sites were chosen (upper back, legs, upper arm, and dorsal feet) due to limited comprehensive, high-quality photography among individuals with Fitzpatrick IV to VI skin types. Sixty-one patients with ichthyosis were represented in the 94 photographs. Interrater reliabilities were determined using intraclass correlation coefficients (ICCs).The researchers found that scale and erythema ICCs varied from 0.97 to 0.99 and from 0.91 to 0.95, respectively, among individuals with Fitzpatrick I to III skin types. The corresponding ICCs varied from 0.97 to 0.99 and from 0.90 to 0.94 among those with Fitzpatrick IV to VI skin types. ISS reliability was demonstrated across phototypes by overlap of ICC confidence intervals."This cross-sectional study shows that validating the ISS in individuals with skin of color is a critical step toward ensuring that assessment tools fully capture disease severity, which is both a criterion for trial enrollment and a measure of therapeutic efficacy," the authors write.Several authors disclosed ties to the biopharmaceutical industry.<a target="_blank" rel="noopener noreferrer" href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2836181">Abstract/Full Text</a><a target="_blank" rel="noopener noreferrer" href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2836180">Editorial</a>

Excellent interrater intraclass correlation coefficients seen for individuals with Fitzpatrick I to III, IV to VI skin types

Ichthyosis Scoring System Can Be Applied Across Phototypes

FRIDAY, June 20, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE).According to the <a target="_blank" rel="noopener noreferrer" href="https://www.mayoclinic.org/diseases-conditions/hives-and-angioedema/symptoms-causes/syc-20354908">Mayo Clinic</a>, angioedema is "a reaction similar to hives that affects deeper layers of the skin. It can appear with hives or alone." Symptoms include welts that form in minutes to hours; swelling, particularly around the eyes, cheeks, or lips; and some mild pain.The approval of Andembry is for use in adult and pediatric patients aged 12 years and older and is self-administered with once-monthly dosing delivered in 15 seconds or less via an autoinjector with a citrate-free formula. Andembry targets factor XIIa, a plasma protein that plays a key role in attacks of swelling in people with HAE.The approval is based on results from a phase 3 study. Findings showed that 62 percent of Andembry-treated patients remained attack-free throughout the six-month study period. Andembry reduced HAE attacks by a median of more than 99 percent compared with placebo. Additionally, Andembry was associated with a 99 percent median reduction and an 88 percent mean reduction in HAE attacks needing on-demand therapy compared with placebo, as well as a 99 percent median reduction and a 90 percent mean reduction in moderate or severe attacks.The most common adverse reactions seen with Andembry were inflammation of the nasal passages and upper throat and abdominal pain (incidence ≥7 percent)."Andembry, the first monoclonal antibody discovered and developed entirely by CSL, offers people living with this life-threatening condition long-term control over their disease along with a convenient administration method," Bill Mezzanotte, M.D., head of research and development at CSL, said in a statement.Approval of Andembry was granted to CSL.<a target="_blank" rel="noopener noreferrer" href="https://newsroom.csl.com/2025-06-16-U-S-Food-and-Drug-Administration-Approves-CSLs-ANDEMBRY-R-garadacimab-gxii-,-the-Only-Prophylactic-Hereditary-Angioedema-HAE-Treatment-Targeting-Factor-XIIa-with-Once-Monthly-Dosing-for-All-Patients-From-the-Start">More Information</a>

The monoclonal antibody is a self-administered injection for prophylactic use to prevent attacks

FDA Approves Once-Monthly Andembry for Hereditary Angioedema

WEDNESDAY, June 11, 2025 (HealthDay News) -- Use of three-dimensional total body photography (3D TBP) can diagnose general skin diseases with high accuracy, according to a study published online June 4 in the Journal of the American Academy of Dermatology.Sebastian Sitaru, M.D., from the Technical University of Munich School of Medicine and Health in Germany, and colleagues examined the value of 3D TBP in general dermatology and examined patient acceptance in an observer agreement study of the diagnoses of 294 patients presenting with skin changes obtained in face-to-face visits versus diagnoses obtained by retrospective analysis of 3D scans with no face-to-face patient visits. Questionnaires were used to evaluate patients' views on 3D TBP.The researchers found that across a broad range of diagnoses in a diverse patient group, primary diagnoses obtained by two senior dermatologists independently reviewing 3D TBP scans matched in 68.4 and 81.1 percent of cases, respectively. Positive views on this technology were mostly expressed by patients, while privacy and shame were identified as barriers."Especially when considering the looming shortage of high-quality dermatological care, 3D TBP therefore has potential to make more efficient use of health care resources, e.g., by enabling underserved regions easier tele-access to dermatologists in better served areas through better standardization of telemedicine," the authors write.<a target="_blank" rel="noopener noreferrer" href="https://www.jaad.org/article/S0190-9622(25)02231-5/fulltext">Abstract/Full Text</a>

Patients mostly expressed positive views on this technology, while privacy and shame were identified as barriers to its use

3D Total Body Photography Helpful for Diagnosing Skin Disease

<div class="raw-html-embed"> <mux-player playback-id="7wSxP02gd01rS2SnARARuIwdRSeRadFw02QwacyLwdYhJ00" env-key="ENV_KEY" metadata-video-title="ISDIN Launch Alert" controls=""></mux-player>
</div>Dr James Del Rosso highlights ISDIN’s innovative Eryfotona Actinica and Eryfotona Actinica Ageless sunscreens, which combine 100% mineral UV protection with photolyases and antioxidants for comprehensive skin protection.&nbsp;In the inaugural Formulation Focus, James Q. Del Rosso, DO reviews two of ISDIN’s photoprotection products: Eryfotona Actinica and Eryfotona Actinica Ageless. These lightweight emulsions combine 100% mineral sunscreen (11% zinc oxide) with DNA repair enzymes (photolyases) and antioxidants for a three-pronged approach to photoprotection.&nbsp;Photolyases, derived from plankton, target cyclobutane pyrimidine dimers—mutagenic DNA damage caused by UV exposure that human skin struggles to repair naturally. By incorporating these enzymes, the formulations aim not only to help prevent sunburn and structural skin damage but also to help repair existing sun damage, which have been known to lead to actinic keratosis or skin cancers like squamous cell carcinoma and melanoma.&nbsp;Eryfotona Actinica is formulated for everyday use with a lightweight, fast-absorbing texture suitable for use under makeup. Eryfotona Actinica Ageless builds on this base with additional ingredients, including peptide Q10 (which stimulates endogenous coenzyme Q10) and a peptide complex—to target signs of skin aging, such as fine lines and wrinkles. Both products include vitamin E for antioxidant protection against visible light and environmental stressors.&nbsp;Dr Del Rosso shares that these innovative formulations represent a new wave in sun care: not just preventing sunburn but addressing the cumulative, long-term damage of sun exposure and offering an aesthetically elegant, easy-to-use formulation that encourages patient compliance.

James Q. Del Rosso, DO reviews two of ISDIN’s photoprotection products: Eryfotona Actinica and Eryfotona Actinica Ageless

Formulation Focus: ISDIN: Advanced Sunscreen Formulations with Photolyases and Antioxidants 

WEDNESDAY, May 14, 2025 (HealthDay News) -- A robust, deep learning model has been developed for the classification of melasma severity, according to a study published online April 16 in Clinical, Cosmetic and Investigational Dermatology.Jun Zhang, from Wuhan First Hospital in China, and colleagues developed an artificial intelligence-assisted real-time melasma severity classification framework based on deep learning and 1,368 anonymized facial images, obtained from clinically diagnosed patients. Six convolutional neural network architectures were trained and evaluated after image preprocessing and Melasma Area and Severity Index-based labeling, and model performance was assessed.The researchers found that the best performance was achieved by GoogLeNet, with accuracy of 0.755 and an F1-score of 0.756. Across severity levels, area under the curve values reached 0.93, 0.86, and 0.94 for mild, moderate, and severe, respectively. GoogLeNet's superior feature attribution was confirmed in a Layer-wise Relevance Propagation analysis."This study demonstrates that deep learning provides a transformative solution for improving the accuracy, consistency, and clinical applicability of melasma severity assessment," the authors write.<a target="_blank" rel="noopener noreferrer" href="https://www.dovepress.com/deep-learning-based-multiclass-framework-for-real-time-melasma-severit-peer-reviewed-fulltext-article-CCID">Abstract/Full Text</a>

Area under the curve values reached 0.93, 0.86, and 0.94 for mild, moderate, and severe melasma with GoogLeNet model

Deep Learning Model Developed for Classification of Melasma Severity

WEDNESDAY, April 16, 2025 (HealthDay News) -- In a special communication published online April 16 in JAMA Dermatology, recommendations are provided for the use of digital photography by dermatologists, with special considerations for skin of color.Madison Grinnell, M.D., from the University of Nebraska Medical Center College of Medicine in Omaha, and colleagues examined best practices for capturing clinically accurate dermatologic digital images, emphasizing techniques to improve photography portraying individuals of color, dermatologic conditions in skin of color, and pigmentary disorders.The authors note that historically, different kinds of photographic technologies have calibrated color correction using participants with light skin, creating inaccurate photographs among those with skin of color. Royal blue backgrounds are often preferred in photographing darker skin, as this color offers increased contrast, without resulting in aberrant hues. When possible, soft diffuse lighting, such as that emitted from an attachable ring light, should be used. Other aspects of photography should be standardized in the clinical setting to include a fixed distance from the patient and dedicated photography space. Specific lighting techniques, such as cross-polarization, may be used in accurately capturing erythema, inflammation, and pigmentary alterations. In addition, several humanistic aspects should be considered when photographing a patient's dermatologic condition."As the U.S. population rapidly diversifies, it is important to increase awareness of photography techniques that can better portray dermatologic processes in diverse skin types," the authors write.One author disclosed ties to the biopharmaceutical industry.<a target="_blank" rel="noopener noreferrer" href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2832862">Abstract/Full Text</a>

Royal blue backgrounds preferred for photographing darker skin, offering increased contrast without aberrant hues

Guidance Provided for Dermatologists Photographing Skin of Color

WEDNESDAY, Feb. 26, 2025 -- Dermatomyositis (DM) and clinically amyopathic DM (CADM) are often misdiagnosed, according to a research letter published online Feb. 26 in JAMA Dermatology.Noting that patients with DM often experience misdiagnosis, Aaron Bao, from the Johns Hopkins University School of Medicine in Baltimore, and colleagues identified common dermatologic mimics of DM, compared misdiagnosis rates between DM and CADM subtypes, and characterized potential implications of misdiagnosis. Adults with confirmed DM or CADM diagnosis and one or more Johns Hopkins dermatologic visits between 2005 and 2023 were included in the study.The analysis included 260 patients: 86 and 174 with CADM and DM, respectively (33 and 67 percent); 125 patients had inflammatory skin disease (ISD). The researchers found that 58 percent of those with ISD received an ISD diagnosis before DM or CADM diagnosis and 36 (29 percent) were misdiagnosed. Seventy-two percent of those with misdiagnosis received their skin evaluation by dermatology. Misdiagnosis rates were higher for the CADM versus DM cohort (44 versus 21 percent), with longer median diagnostic delays (236 versus 114 days). The most prevalent ISDs were unspecified dermatitis and eczema (22 and 19 percent, respectively). The highest misdiagnosis rates were seen for cutaneous lupus erythematosus and eczema before DM or CADM diagnosis (67 and 29 percent, respectively). Higher one-year hospitalization rates were seen for patients with misdiagnosis (54 versus 33 percent)."Eczema emerged as a notable mimic, possibly due to similar distributions and morphologic features," the authors write.One author disclosed ties to the biopharmaceutical industry.

Misdiagnosis rates higher for the clinically amyopathic DM cohort versus DM cohort, with longer median diagnostic delays

Dermatomyositis, Clinically Amyopathic Dermatomyositis Often Misdiagnosed

WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Formulation characteristics can explain much of the observed variation in benzene levels of over-the-counter benzoyl peroxide-containing products, according to a research letter published online Feb. 12 in JAMA Dermatology.John S. Barbieri, M.D., from Brigham and Women's Hospital in Boston, and colleagues examined the association of formulation with benzene levels of over-the-counter benzoyl peroxide-containing products. The vehicles for 111 products that had their benzene levels examined were evaluated.The researchers found that leave-on products were associated with significantly lower concentrations of benzene (coefficient, −5.83). No significant association was seen between benzoyl peroxide concentration and benzene concentrations. A weak, but statistically significant, association was seen between days to expiration date and benzene concentration (coefficient, −0.010). Conditions consistent with hot processing were associated with increased benzene concentrations (coefficient, 7.34) in multivariable regression models adjusted for benzoyl peroxide concentration, product type, and days until expiration date. Butylated hydroxytoluene was associated with reduced benzene concentrations (coefficient, −8.15). Benzoic acid was associated with numerically, but not significantly, lower benzene concentrations."These results raise important hypotheses for potential strategies to reduce benzene in benzoyl peroxide-containing products, including excipient selection and stricter temperature controls during formulation and distribution," the authors write.Several authors disclosed ties to the pharmaceutical and skin care industries.<a target="_blank" rel="noopener noreferrer" href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2830217">Abstract/Full Text (subscription or payment may be required)</a>

Leave-on products linked to lower concentrations of benzene; increased concentrations seen in conditions consistent with hot processing

Benzoyl Peroxide Formulation Characteristics Explain Variation in Benzene Levels

TUESDAY, Jan. 7, 2025 (HealthDay News) -- Videoconferencing and the application of filters are significantly associated with a heightened interest in cosmetic procedures, according to a study published online Jan. 6 in the Journal of Clinical and Aesthetic Dermatology.Payal M. Patel, M.D., from Massachusetts General Hospital in Boston, and colleagues examined the association between the increased use of videoconferencing and image-enhancing software filters during the COVID-19 pandemic and the corresponding rise in interest in cosmetic procedures. The analysis included survey results from 505 U.S. adults.The researchers found that videoconferencing was frequent, with 88.6 percent using it more than three days a week; 68.1 percent reported using "touch-up my appearance" filters more than half the time. The desire for cosmetic procedures was influenced by videoconferencing in 55.9 percent of participants, while 57.8 percent were influenced by filter use. Two-thirds of respondents reported frequent self-viewing, which was strongly associated with interest in cosmetic procedures. Filter use was significantly predicted by higher income (odds ratio, 2.436) and frequent self-viewing behavior (odds ratio, 5.034). In frequent self-viewers, mask wearing was associated with increased self-esteem (68.8 percent) and a reduced desire for cosmetic procedures (67.4 percent)."These insights are vital for dermatologists in understanding patient motivations, managing expectations, and fostering realistic treatment outcomes," the authors write.<a target="_blank" rel="noopener noreferrer" href="https://jcadonline.com/videoconferencing-dysmorphia-the-impact-on-self-perception-and-desire-for-cosmetic-procedures/">Abstract/Full Text</a>

Interest in cosmetic procedures significantly predicted by frequent self-viewing behavior

'Videoconferencing Dysmorphia' Drives Interest in Cosmetic Procedures

WEDNESDAY, Nov. 6, 2024 -- Pain is prevalent among Mohs surgeons, most commonly at the neck, upper back, and lower back, according to a study published in the September issue of SKIN.Timothy J. Orlowski, M.D., from the University of Alabama at Birmingham, and colleagues conducted a cross-sectional survey study among members of the American College of Mohs Surgery to examine the prevalence and characteristics of pain and discomfort among trained Mohs surgeons. A total of 107 male and female surgeons responded.The researchers found that chronic pain was reported by 88.7 percent of participants, with the neck, upper back, and lower back the most common anatomic locations for pain (54.2, 38.2, and 33.6 percent, respectively). Compared with female respondents, male respondents less often complained of upper back pain but more often reported lower back pain (odds ratios, 0.349 and 2.462, respectively). Regular pain-relieving medication use was more likely to be reported when participants were suffering from neck or upper back pain (odds ratios, 4.665 and 3.366, respectively). The likelihood of reporting neck pain was lower for respondents regularly using sit-stand stools."Not only are Mohs surgeons at risk for musculoskeletal injury, but Mohs histology technicians and other ancillary staff also remain vulnerable," the authors write. "Future collaboration with current educators, occupational health professionals, and physical and occupational therapists may provide insight on future ergonomic education and modifications."

Male surgeons less often complain of upper back pain, but more often report lower back pain than female surgeons

Pain Prevalent Among Mohs Surgeons, Reported by 88.7 Percent

WEDNESDAY, Oct. 2, 2024 -- The incidence of epidermal necrolysis (EN) is 2.6 cases per million person-years, but overall mortality is 34 percent, according to a study published online Oct. 2 in JAMA Dermatology.Thomas Bettuzzi, M.D., M.P.H., from the Hôpital Henri Mondor in Créteil, France, and colleagues conducted a cohort study using French Health System data from Jan. 1, 2013, to Dec. 31, 2022, to assess the incidence of and compare factors associated with in-hospital and postdischarge mortality among patients with EN. Data were included for 1,221 adult patients with EN.The researchers found that the incidence was 2.6 cases per million person-years. The in-hospital and postdischarge mortality rates were 19 and 15 percent, respectively, for an overall mortality of 34 percent. Factors associated with in-hospital mortality included age (adjusted hazard ratio [AHR], 1.03 per year of age), history of cancer (AHR, 2.04), dementia (AHR, 1.85), liver disease (AHR, 1.81), and EN severity (AHR, 2.14 for toxic epidermal necrolysis versus Stevens-Johnson syndrome). There was no association observed for EN initial severity with mortality after hospital discharge, but the associations for acute complications persisted (AHRs, 2.14 and 2.44 for acute kidney injury and sepsis, respectively). Ophthalmologic and mood disorders were the main sequelae."Despite EN being a rare condition, it is associated with high in-hospital and postdischarge mortality and a high burden of sequelae," the authors write.

Factors associated with in-hospital mortality include age, history of cancer, dementia, liver disease, EN severity

Incidence of Epidermal Necrolysis 2.6 Cases Per Million Person-Years

WEDNESDAY, Oct. 2, 2024 -- An artificial intelligence (AI) model, VisualDx, demonstrates diagnostic bias for images in the Fitzpatrick I to III subgroup, according to a study published online Sept. 15 in SKIN.Katrina D. Cirone, M.D., from Western University in London, Ontario, Canada, and colleagues examined whether the AI model VisualDx performs differently when classifying conditions across different skin phenotypes. Sixteen common conditions were included in the image dataset. For each condition, there were three subgroups: "Fitzpatrick I to III," "Fitzpatrick IV to VI," and "Processed," which contained images from the Fitzpatrick I to III subgroup altered to resemble skin with rich pigmentation. A differential diagnosis list was obtained by processing images with VisualDx.The researchers found the highest sensitivity (97 percent) for hidradenitis suppurativa, prurigo nodularis, and tinea versicolor across all subgroups. The lowest sensitivity was seen for atopic dermatitis, postinflammatory hyperpigmentation, and basal cell carcinoma (23, 23, and 27 percent, respectively). For all conditions except acanthosis nigricans, melasma, and melanoma, significantly greater diagnostic sensitivity was noted in the Fitzpatrick I to III subgroup than the Fitzpatrick IV to VI and Processed subgroups. A reduction in sensitivity and specificity was seen for all conditions for the processed images."Future training of AI diagnostic tools should be done using more comprehensive databases so that diagnosis can be accurately performed across all skin phenotypes," the authors write.

VisualDX demonstrated significantly greater sensitivity for Fitzpatrick I to III subgroup than Fitzpatrick IV to VI and a processed image subgroup

AI Model Exhibits Diagnostic Bias Towards Fitzpatrick I to III Subgroup

WEDNESDAY, Aug. 28, 2024 -- Tranexamic acid and platelet-rich plasma (PRP) combined with microneedling are effective for the treatment of melasma, according to a study published in the July issue of SKIN.Masoumeh Roohaninasab, M.D., from the Iran University of Medical Sciences in Tehran, and colleagues examined the efficacy of PRP combined with microneedling versus tranexamic acid combined with microneedling for melasma. The study employed a split-face comparative design in 20 female patients with melasma (mean age, 41 years). Participants underwent four sessions of PRP with microneedling on one side of the face and 5 percent tranexamic acid with microneedling on the other side.The researchers observed a substantial decrease in the median ΔE (skin erythema) using Visioface during follow-up, reflecting color changes (mean difference, 6.66 and 1.90 in the tranexamic acid + microneedling group and in the PRP + microneedling group, respectively). A notable reduction in melanin was seen in the tranexamic acid + microneedling group. High patient satisfaction was seen with both treatments. Only minor transient side effects were seen, and both procedures were well tolerated."This study demonstrates that the combination of both PRP and tranexamic acid with microneedling significantly improves melasma," the authors write. "While no superiority was observed between these two approaches, they prove to be a promising combination or alternative for melasma treatment due to their high efficacy, safety, tolerability, and patient satisfaction levels."

Both platelet-rich plasma and tranexamic acid combined with microneedling improved melasma in split-face study

Dermatology Condition Center

Featured in Dermatology

Gaining Expertise in Prior Authorizations and Biologics at PAMS Chicago

Latest Dermatology Videos

From Therapy to Patient Access at PAMS Chicago

Improving Efficiencies and Professional Growth at PAMS Chicago

Featured CME on Dermatology

Dermatology Episodes to Explore

Young Guns in Dermatology 2: Being a Dermatology Detective

From Residency to Real Life: Avoiding Burnout Before It Starts

Dermatology News & Research

Dermatoscopes Compared for Dermoscopy Performance, Teledermatology Use

Introducing Amy Jones and PANP360: A New Era for PAs and NPs in Dermatology

Study Compares Treatment Modalities for Management of Keloids